Pure Global
NCT05686616

SGLT2 Inhibitor for Severe Tricuspid Regurgitation

Multicenter, Randomized, Controlled Trial to Assess the Efficacy of Sodium Glucose Cotransporter-2 Inhibitor add-on Treatment in Patients With Severe Tricuspid Regurgitation
Samsung Medical Center·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Tricuspid Regurgitation
Drug/Device/Intervention
Dapagliflozin Propanediol Hydrate 12.3 mg
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Samsung Medical Center
Location
Seoul, South Korea
Timeline & enrollment
Phase
N/A
Start date
Apr 13, 2022
End date
Mar 03, 2025
Enrollment
72 participants
Primary outcome

Difference of RVESVi by CMR from baseline to 12 months follow-up (∆RVESVi)

Summary

The purpose of this study to identify the efficacy of sodium glucose cotransporter 2
 inhibitors add-on treatment on right ventricular remodeling and the amount of severe
 tricuspid regurgitation (TR) in patients with isolated severe TR.

ICD-10 classifications
Tricuspid stenosisTricuspid stenosis with insufficiencyNonrheumatic tricuspid (valve) stenosisTricuspid insufficiencyNonrheumatic tricuspid (valve) stenosis with insufficiency
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05686616
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05686616 through Pure Global AI's free database. This phase not specified trial is sponsored by Samsung Medical Center and is currently Recruiting. The study focuses on Tricuspid Regurgitation. Target enrollment is 72 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.